Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Constructive evidenceCoverage 5/5 core metricsOperating margin changed -0.1 percentage points from the prior annual period.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- Operating margin was stable
Operating margin changed -0.1 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-28.
- No current rule-based risk flags
11 filing-based checks were evaluable.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Revenue expanded
Latest reported annual revenue changed +3.7% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-28.
- Free cash flow was positive
Latest reported free cash flow was $509M.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-28.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-11-22
- Latest period end
- 2025-12-28
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Life Sciences$1.43B50.1%+2.3% yoy
- Diagnostics$1.42B49.9%+5.1% yoy
Members sum to the consolidated $2.86B for this period.
- Product$2.39B83.7%+2.2% yoy
- Service$466M16.3%+11.8% yoy
Members sum to the consolidated $2.86B for this period.
- Total International$1.73Bshare n/a+4.4% yoy
- Americas$1.26Bshare n/a+2.7% yoy
- United States$1.13Bshare n/a+2.6% yoy
- Other International$1Bshare n/a+7.4% yoy
- Europe$825Mshare n/a+11.1% yoy
- Asia$775Mshare n/a-1.8% yoy
- China$425Mshare n/a-5.5% yoy
- Germany$178Mshare n/a+9.3% yoy
- +1 more member in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Diagnostics$371M50.8%no prior
- Life Sciences$359M49.2%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2025-12-28 · among 4,026 US-listed filers · 307 in Healthcare| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $2.9B | 71stof 3,198 top third | 77thof 280 top third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | 3.7% | 41stof 3,041 middle third | 31stof 268 bottom third |
Operating margin operating income ÷ revenue | 12.5% | 73rdof 2,733 top third | 79thof 268 top third |
Net margin net income ÷ revenue | 8.4% | 67thof 3,157 top third | 75thof 279 top third |
Free-cash-flow margin (operating cash flow − |capex|) ÷ revenue | 17.8% | 80thof 2,598 top third | 88thof 252 top third |
Return on equity net income ÷ stockholders' equity (positive equity only) | 3.3% | 48thof 3,488 middle third | 62ndof 279 middle third |
Stock comp ÷ revenue stock-based compensation ÷ revenue · lower is ranked higher | 0.8% | 73rdof 2,809 top third | 87thof 266 top third |
Days sales outstanding receivables ÷ revenue × 365 · lower is ranked higher | 95 days | 12thof 2,340 bottom third | 11thof 255 bottom third |
Net debt ÷ operating cash flow net debt ÷ operating cash flow (OCF > 0) · lower is ranked higher | 2.9× | 42ndof 1,501 middle third | 41stof 113 middle third |
Cash conversion operating cash flow ÷ net income (net income > 0) | 2.4× | 76thof 2,222 top third | 77thof 124 top third |
Cash-flow accrual ratio (net income − operating cash flow) ÷ average total assets · lower is ranked higher | -2.8% | 36thof 3,803 middle third | 22ndof 295 bottom third |
Balance-sheet accrual ratio change in net operating assets ÷ average net operating assets · lower is ranked higher | -7.4% | 71stof 3,262 top third | 71stof 256 top third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
latest fiscal year ending 2025-12-28 · accruals and cash conversion as filedPer fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.
Point-in-time ledger
first-reported vs latest filing · periods since 2020-01-01 · 33 changed periods, 30 largest shown| Line item | Period | First reported | Latest filing | Change | Filings |
|---|---|---|---|---|---|
| Deferred revenue (current) DeferredRevenueCurrent | balance at 2022-01-02 | $226M 10-K 2022-03-03 | $138M 10-K 2023-03-01 | -39.0% | first · latest |
| Receivables AccountsReceivableNetCurrent | balance at 2022-01-02 | $1.02B 10-K 2022-03-03 | $708M 10-K 2023-03-01 | -30.9% | first · latest · 5 filings carry it |
| Revenue RevenueFromContractWithCustomerExcludingAssessedTax | fiscal year 2021-01-03 | $3.78B 10-K 2021-03-02 | $2.66B 10-K 2023-03-01 | -29.6% | first · latest · 3 filings carry it |
| Revenue RevenueFromContractWithCustomerExcludingAssessedTax | quarter 2022-07-03 | $1.23B 10-Q 2022-08-09 | $896M 10-Q 2023-08-09 | -27.2% | first · latest |
| Revenue RevenueFromContractWithCustomerExcludingAssessedTax | quarter 2021-10-03 | $1.17B 10-Q 2021-11-09 | $861M 10-Q 2022-11-14 | -26.2% | first · latest |
| Revenue RevenueFromContractWithCustomerExcludingAssessedTax | fiscal year 2022-01-02 | $5.07B 10-K 2022-03-03 | $3.83B 10-K 2024-02-27 | -24.5% | first · latest · 3 filings carry it |
| Revenue RevenueFromContractWithCustomerExcludingAssessedTax | quarter 2022-04-03 | $1.26B 10-Q 2022-05-10 | $963M 10-Q 2023-05-12 | -23.5% | first · latest |
| Goodwill Goodwill | balance at 2021-01-03 | $3.45B 10-K 2021-03-02 | $2.64B 10-K 2023-03-01 | -23.4% | first · latest · 6 filings carry it |
| Depreciation and amortization DepreciationDepletionAndAmortization | fiscal year 2021-01-03 | $247M 10-K 2021-03-02 | $202M 10-K 2023-03-01 | -18.2% | first · latest · 3 filings carry it |
| Capital expenditure PaymentsToAcquirePropertyPlantAndEquipment | fiscal year 2021-01-03 | $77.5M 10-K 2021-03-02 | $63.6M 10-K 2023-03-01 | -17.9% | first · latest · 3 filings carry it |
| Capital expenditure PaymentsToAcquirePropertyPlantAndEquipment | fiscal year 2022-01-02 | $99.9M 10-K 2022-03-03 | $86M 10-K 2024-02-27 | -13.9% | first · latest · 3 filings carry it |
| Depreciation and amortization DepreciationDepletionAndAmortization | fiscal year 2022-01-02 | $358M 10-K 2022-03-03 | $311M 10-K 2024-02-27 | -13.0% | first · latest · 3 filings carry it |
| Operating income OperatingIncomeLoss | quarter 2021-10-03 | $222M 10-Q 2021-11-09 | $196M 10-K 2023-03-01 | -11.9% | first · latest · 3 filings carry it |
| Operating income OperatingIncomeLoss | fiscal year 2021-01-03 | $979M 10-K 2021-03-02 | $867M 10-K 2023-03-01 | -11.4% | first · latest · 3 filings carry it |
| Goodwill Goodwill | balance at 2022-01-02 | $7.42B 10-K 2022-03-03 | $6.63B 10-K 2024-02-27 | -10.6% | first · latest · 6 filings carry it |
| Stock-based compensation ShareBasedCompensation | fiscal year 2022-01-02 | $32.8M 10-K 2022-03-03 | $29.7M 10-K 2024-02-27 | -9.5% | first · latest · 3 filings carry it |
| Depreciation and amortization DepreciationDepletionAndAmortization | quarter 2022-04-03 | $120M 10-Q 2022-05-10 | $109M 10-Q 2023-05-12 | -8.9% | first · latest |
| Capital expenditure PaymentsToAcquirePropertyPlantAndEquipment | quarter 2022-04-03 | $29.4M 10-Q 2022-05-10 | $27M 10-Q 2023-05-12 | -8.4% | first · latest |
| Stock-based compensation ShareBasedCompensation | fiscal year 2021-01-03 | $29.1M 10-K 2021-03-02 | $26.9M 10-K 2023-03-01 | -7.6% | first · latest · 3 filings carry it |
| Operating income OperatingIncomeLoss | quarter 2021-07-04 | $332M 10-Q 2021-08-10 | $308M 10-K 2023-03-01 | -7.4% | first · latest · 3 filings carry it |
| Operating income OperatingIncomeLoss | quarter 2022-07-03 | $251M 10-Q 2022-08-09 | $232M 10-Q 2023-08-09 | -7.3% | first · latest · 3 filings carry it |
| Intangibles IntangibleAssetsNetExcludingGoodwill | balance at 2022-01-02 | $4.06B 10-K 2022-03-03 | $3.82B 10-K 2023-03-01 | -5.9% | first · latest · 5 filings carry it |
| Operating income OperatingIncomeLoss | fiscal year 2022-01-02 | $1.33B 10-K 2022-03-03 | $1.26B 10-K 2024-02-27 | -5.5% | first · latest · 3 filings carry it |
| Stock-based compensation ShareBasedCompensation | quarter 2022-04-03 | $15.3M 10-Q 2022-05-10 | $14.4M 10-Q 2023-05-12 | -5.4% | first · latest |
| Cash CashAndCashEquivalentsAtCarryingValue | balance at 2022-07-03 | $361M 10-Q 2022-08-09 | $346M 10-Q 2023-08-09 | -4.2% | first · latest |
| Cash CashAndCashEquivalentsAtCarryingValue | balance at 2021-01-03 | $402M 10-K 2021-03-02 | $387M 10-K 2023-03-01 | -3.7% | first · latest · 6 filings carry it |
| Cash CashAndCashEquivalentsAtCarryingValue | balance at 2021-10-03 | $487M 10-Q 2021-11-09 | $472M 10-Q 2022-11-14 | -3.1% | first · latest |
| Operating income OperatingIncomeLoss | quarter 2022-04-03 | $255M 10-Q 2022-05-10 | $262M 10-Q 2023-05-12 | +2.8% | first · latest · 3 filings carry it |
| Operating income OperatingIncomeLoss | quarter 2021-04-04 | $468M 10-Q 2021-05-11 | $455M 10-K 2023-03-01 | -2.7% | first · latest · 3 filings carry it |
| Cash CashAndCashEquivalentsAtCarryingValue | balance at 2022-01-02 | $618M 10-K 2022-03-03 | $603M 10-K 2024-02-27 | -2.4% | first · latest · 6 filings carry it |
First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding; share counts re-presented by an integer split ratio are listed as split adjustments, not restatements. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.
Notes by disclosure type
debt, leases, revenue, segments, contingencies, taxes and more · the filer's own wordsCommitments and contingencies · 3,069 characters as filed
Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (PRP) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Companys responsibility is established and when the cost can be reasonably estimated. The Company has accrued $10.8 million and $14.2 million as of December 28, 2025 and December 29, 2024, respecti vely, in accrued expenses and other current liabilities, which represents its managements estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. The Companys environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to con …
CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing
Debt · 3,688 characters as filed
Debt The Companys debt consisted of the following: December 28, 2025 Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ $ $ (2,857) $ (2,857) 1.900% Senior Unsecured Notes due in 2028 (2028 Notes) 500,000 (148) (1,791) 498,061 3.3% Senior Unsecured Notes due in 2029 (2029 Notes) 850,000 (1,169) (3,235) 845,596 2.55% Senior Unsecured Notes due in March 2031 (March 2031 Notes) 400,000 (75) (1,952) 397,973 2.250% Senior Unsecured Notes due in September 2031 (September 2031 Notes) 500,000 (919) (2,641) 496,440 3.625% Senior Unsecured Notes due in 2051 (2051 Notes) 400,000 (3) (3,974) 396,023 Total Long-Term Debt 2,650,000 (2,314) (16,450) 2,631,236 Current Portion of Long-Term Debt: 500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (2026 Notes) 589,450 (343) (279) 588,828 Total Current Portion of Long-Term Debt 589,450 (343) (279) 588,828 Total Debt $ 3,239,450 $ (2,657) $ (16,729) $ 3,220,064 December 29, 2024 Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ $ $ (1,208) $ (1,208) 2026 Notes 521,700 (834) (780) 520,086 2028 Notes 500,000 (200) (2,408) 497,392 2029 Notes 850,000 (1,448) (4,010) 844,542 March 2031 Notes 400,000 (88) (2,294) 397,618 September 2031 Notes 500,000 (1,065) (3,059) 495,876 2051 Notes 400,000 (4) ( …
DebtDisclosureTextBlock · excerpt; the full note is in the filing
Revenue disaggregation · 1,174 characters as filed
In the following tables, revenue is disaggregated by primary geographical market and major good and service lines. Reportable Segments For the fiscal year ended December 28, 2025 December 29, 2024 December 31, 2023 Life Sciences Diagnostics Total Life Sciences Diagnostics Total Life Sciences Diagnostics Total (In thousands) Primary geographical markets Americas $ 750,857 $ 505,104 $ 1,255,961 $ 745,206 $ 477,881 $ 1,223,087 $ 759,782 $ 455,831 $ 1,215,613 Europe 343,507 481,471 824,978 315,173 427,441 742,614 344,713 402,310 747,023 Asia 336,740 438,372 775,112 338,222 451,103 789,325 353,697 434,238 787,935 $ 1,431,104 $ 1,424,947 $ 2,856,051 $ 1,398,601 $ 1,356,425 $ 2,755,026 $ 1,458,192 $ 1,292,379 $ 2,750,571 Major goods/service lines Life Sciences Solutions $ 1,194,728 $ $ 1,194,728 $ 1,197,802 $ $ 1,197,802 $ 1,279,903 $ $ 1,279,903 Software 236,376 236,376 200,799 200,799 178,289 178,289 Immunodiagnostics 869,908 869,908 828,627 828,627 787,394 787,394 Reproductive health 555,039 555,039 527,798 527,798 504,985 504,985 $ 1,431,104 $ 1,424,947 $ 2,856,051 $ 1,398,601 $ 1,356,425 $ 2,755,026 $ 1,458,192 $ 1,292,379 $ 2,750,571 …
DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing
Share-based compensation · 8,065 characters as filed
Stock Plans Stock-Based Compensation: The Companys 2019 Incentive Plan (the 2019 Plan) authorizes the issuance of stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and cash awards as part of the Companys compensation programs. The 2019 Plan replaced the Companys 2009 Incentive Plan (the 2009 Plan). Upon shareholder approval of the 2019 Plan, 6.25 million shares of the Companys common stock, as well as shares of the Companys common stock previously granted under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price subject to a contractual repurchase right, became available for grant under the 2019 Plan. Awards granted under the 2009 Plan prior to its expiration remain outstanding. As part of the Companys compensation programs, the Company also offers shares of its common stock under its Employee Stock Purchase Plan. The following table summarizes total pre-tax compensation expense recognized related to the Companys stock options, restricted stock, restricted stock units, performance restricted stock units and stock grants, included in the Companys consolidated statements of operations: December 28, 2025 December 29, 2024 December 31, 2023 (In thousands) Cost of product and service revenue $ 2,149 $ 2,495 $ 4,224 Research and development expenses 1,577 3,863 5,276 Selling, general and administrative expenses 19,121 31,451 31 …
DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing
Fair value · 8,973 characters as filed
Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities, accounts receivable and notes receivable. The Company believes it had no significant concentrations of credit risk as of December 28, 2025. The Companys financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Companys currency risk, and acqu isition and divestiture related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial assets or liabilitys classification within the hierarchy is determined based on the lowest level input that is significant t …
FairValueDisclosuresTextBlock · excerpt; the full note is in the filing
Goodwill and intangibles · 1,787 characters as filed
Goodwill and Intangible Assets, Net The changes in the carrying amount of goodwill for fiscal years 2025 and 2024 are as follows: Life Sciences Diagnostics Consolidated (In thousands) Balance at December 31, 2023 $ 4,587,938 $ 1,945,612 $ 6,533,550 Foreign currency translation (46,471) (23,460) (69,931) Balance at December 29, 2024 4,541,467 1,922,152 6,463,619 Foreign currency translation 105,495 44,379 149,874 Other 98,000 (98,000) Balance at December 28, 2025 $ 4,744,962 $ 1,868,531 $ 6,613,493 Amortizable intangible asset balances at December 28, 2025 and December 29, 2024 were as follows: December 28, 2025 December 29, 2024 (In thousands) Patents $ 27,592 $ 27,808 Less: Accumulated amortization (26,524) (26,293) Net patents 1,068 1,515 Trade names and trademarks 150,103 142,588 Less: Accumulated amortization (102,234) (87,824) Net trade names and trademarks 47,869 54,764 Licenses 27,561 27,164 Less: Accumulated amortization (19,849) (17,855) Net licenses 7,712 9,309 Core technology 1,624,925 1,561,831 Less: Accumulated amortization (921,325) (735,532) Net core technology 703,600 826,299 Customer relationships 2,870,384 2,807,909 Less: Accumulated amortization (1,283,630) (1,058,875) Net customer relationships 1,586,754 1,749,034 Net amortizable intangible assets $ 2,347,003 $ 2,640,921 Total amortization expense related to amortizable intangible assets was $335.6 million in fiscal year 2025, $359.4 million in fiscal year 2024 and $365.1 million in fiscal year 2023. Estim …
GoodwillAndIntangibleAssetsDisclosureTextBlock · excerpt; the full note is in the filing
Pensions and post-retirement benefits · 14,597 characters as filed
Employee Benefit Plans Savings Plan: The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Savings plan expense was $13.8 million in fiscal year 2025, $13.3 million in fiscal year 2024, and $15.0 million in fiscal year 2023. Pension Plans: The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan is closed to new hires and plan benefits have been frozen. The plans provide benefits that are based on an employees years of service and compensation near retirement. In December 2024, the Company entered into an annuity purchase agreement to irrevocably transfer a portion of the U.S. pension benefit obligation to a third-party insurance company. The annuity purchase price was $94.1 million and was funded from U.S. pension plan assets. The resulting settlement of the U.S. pension plan was not material and is included in the actuarial gains and losses recognized during fiscal year 2024. In January 2025, the Company executed a sale of its United Kingdom (UK) pension plan to a third party as part of a multi-year buy-out plan. Following satisfaction of all obligations in the buy-out agreement, excess plan assets of $2.7 million, net of taxes, reverted to t …
PensionAndOtherPostretirementBenefitsDisclosureTextBlock · excerpt; the full note is in the filing
Restructuring · 2,351 characters as filed
Restructuring and Other Costs Restructuring and other costs in fiscal year 2025 primarily included charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. In fiscal year 2025, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the Companys workforce. Restructuring and other costs in fiscal years 2024 and 2023 primarily included charges for workforce reductions and facility consolidations, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. Severance actions associated with facility consolidations and cost reduction initiatives were not material to the Companys overall workforce in both fiscal years. Restructuring and other costs, included in the selling, general and administrative expenses in the consolidated statements of operations, by segment are as follows: December 28, 2025 December 29, 2024 December 31, 2023 (In thousands) Life Sciences $ 15,552 $ 4,532 $ 6,203 Diagnostics 39,337 12,539 15,465 Corporate 1,043 383 4,933 $ 55,932 $ 17,454 $ 26,601 The following table summarizes the changes in the Companys accrued restructuring balance for fiscal year 202 5. The changes in …
RestructuringAndRelatedActivitiesDisclosureTextBlock · excerpt; the full note is in the filing
Revenue recognition · 8,038 characters as filed
Revenue For arrangements with multiple performance obligations, the Company accounts for individual products and services separately if they are distinct - i.e., if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The consideration (including any discounts) is allocated to each performance obligation in an arrangement based on relative stand-alone selling prices. The stand-alone selling prices are determined based on the prices at which the Company separately sells the products, extended warranties, and services. For items that are not sold separately, the Company estimates stand-alone selling prices by reference to the amount charged for similar items on a stand-alone basis. The Company sells products and services predominantly through its direct sales force, and the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty). In instances where the timing of revenue recognition differs from the timing of invoicing, the Company determined that the contracts generally do not include a significant financing component. In limited circumstances where the Company provides the customer with a significant benefit of financing, the Company uses the practical exp …
RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing
Segment reporting · 5,893 characters as filed
Segment and Geographic Area Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The CODM of the Company is the Chief Executive Officer (CEO). The CEO evaluates the performance of its operating segments based on revenue and operating income as adjusted for certain items. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1. Effective at the beginning of fiscal year 2025, the Company implemented changes to its operating model. The majority of the Company s Applied Genomics business, previously reported as part of the Diagnostics segment, has been integrated into a newly formed Life Sciences Solutions business, encompassing all Life Sciences reagents and consumables, instruments and services, as well as technology and licensing, which is reported as part of the Life Sciences segment. Beginning in fiscal year 2025, the Life Sciences segment consists of Life Sciences Solutions and Software, while the Diagnostics segment consists of Immunodiagnostics and Reproductive Health. The effect of the change is not significant. Prior period financial information has been reclassified to reflect this new segment composition for consistent comparison. The Company has included the expenses for its corporate headquarters, such as legal, t …
SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing
Stockholders' equity · 4,329 characters as filed
Stockholders Equity Comprehensive Income: The components of accumulated other comprehensive (loss) income consisted of the following: Foreign Currency Translation Adjustment, net of tax Unrecognized Prior Service Costs, net of tax Unrealized (Losses) Gains on Securities, net of tax Accumulated Other Comprehensive (Loss) Income (In thousands) Balance, January 1, 2023 $ (446,664) $ (798) $ (35) $ (447,497) Current year change 80,172 (181) 79,991 Reclassification to retained earnings 90,814 90,814 Balance, December 31, 2023 (275,678) (798) (216) (276,692) Current year change (119,260) (153) (119,413) Balance, December 29, 2024 (394,938) (798) (369) (396,105) Current year change 173,876 94 173,970 Balance, December 28, 2025 $ (221,062) $ (798) $ (275) $ (222,135) The unrealized foreign exchange (gains) losses, net of income taxes, on intercompany debt for which repayment is not anticipated in the foreseeable future that was recorded in AOCI for the fiscal years 2025, 2024 and 2023 were $(165.3) million, $(0.9) million and $11.3 million, respectively. Income taxes related to foreign currency translation adjustments recognized in AOCI during fiscal year 2025 were $59.5 million. Income taxes related to foreign currency translation adjustments recognized in AOCI during fiscal years 2024 and 2023 were not material. Stock Repurchases: On October 24, 2024, the Board authorized the Company to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a stock repur …
StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing
Subsequent events · 617 characters as filed
Subsequent Events Subsequent to fiscal year 2025, the Company completed its acquisition of Advanced Chemistry Development Inc. (ACD/Labs) for $72 million in cash paid at the closing and up to $8 million in contingent consideration to be paid in cash based on the achievement of certain revenue metrics through 2028. AC D/Labs is based in Toronto, Canada, has approximately 200 employees, and is a provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. ACD/Labs will be recognized in the Life Sciences segment. …
SubsequentEventsTextBlock · excerpt; the full note is in the filing
Business combinations · 1,105 characters as filed
Business Combinations Acquisitions in fiscal year 2026 During the first quarter of fiscal year 2026, the Company completed its acquisition of Advanced Chemistry Development Inc. (ACD/Labs) for $72.0 million in cash paid at closing and up to $8.0 million in contingent consideration to be paid in cash based on the achievement of certain revenue metrics through 2028. ACD/Labs is based in Toronto, Canada, has approximately 200 employees, and is a provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. The Company has reported the operations for this acquisition within the results of the Companys Life Sciences segment from the acquisition date. Identifiable definite-lived intangible assets, such as developed technology ($30.1 million), trade names and trademarks ($0.8 million), customer relationships ($18.2 million) and backlog ($1.1 million), acquired as part of this acquisition had a weighted-average amortization period of 11.3 years. The Company has recorded $31.8 million of goodwill. …
BusinessCombinationDisclosureTextBlock · excerpt; the full note is in the filing
Commitments and contingencies · 3,115 characters as filed
Contingencies The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (PRP) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Companys responsibility is established and when the cost can be reasonably estimated. The Company has accrued $10.6 million and $10.8 million as of July 5, 2026 and December 28, 2025, respectively, which represents its managements estimate of the cost of the remediation of known environmental matters and does not include any potential liability for related personal injury or property damage claims. These amounts were included in accrued expenses and other current liabilities. The Companys environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant …
CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing
Debt · 2,175 characters as filed
Debt The Companys debt consisted of the following: July 5, 2026 Outstanding Principal Unamortized Debt Discount Unamortized Debt Issuance Costs Net Carrying Amount (In thousands) Long-Term Debt: Senior Unsecured Revolving Credit Facility $ $ $ (2,499) $ (2,499) 1.900% Senior Unsecured Notes due in 2028 500,000 (121) (1,458) 498,421 3.3% Senior Unsecured Notes due in 2029 850,000 (1,014) (2,811) 846,175 2.55% Senior Unsecured Notes due in March 2031 400,000 (67) (1,763) 398,170 2.250% Senior Unsecured Notes due in September 2031 500,000 (840) (2,413) 496,747 3.625% Senior Unsecured Notes due in 2051 400,000 (3) (3,917) 396,080 Total Long-Term Debt 2,650,000 (2,045) (14,861) 2,633,094 Current Portion of Long-term Debt: 500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (2026 Notes) 572,200 (24) (20) 572,156 Total $ 3,222,200 $ (2,069) $ (14,881) $ 3,205,250 On January 7, 2025 , the Company entered into a senior unsecured revolving credit facility with a five-year term and a borrowing capacity of $1.5 billion available through January 7, 2030 . Borrowings will bear interest, payable quarterly or, if earlier, at the end of any interest period, at the Companys option at either (a) the base rate (as described in the credit agreement), or (b) the Term Secured Overnight Financing Rate (Term SOFR) (as described in the credit agreement), in each case plus a percentage spread based on the credit rating of the Companys debt. The base rate is the highest of (a) the Federal Funds …
DebtDisclosureTextBlock · excerpt; the full note is in the filing
Revenue disaggregation · 818 characters as filed
Disaggregated revenue by primary geographical markets and major goods and service lines are as follows: Reportable Segments Three Months Ended July 5, 2026 June 29, 2025 Life Sciences Diagnostics Total Life Sciences Diagnostics Total (In thousands) Primary geographical markets Americas $ 183,575 $ 142,008 $ 325,583 $ 197,071 $ 126,509 $ 323,580 Europe 89,478 139,563 229,041 84,298 119,334 203,632 Asia 85,646 89,418 175,064 84,529 108,543 193,072 $ 358,699 $ 370,989 $ 729,688 $ 365,898 $ 354,386 $ 720,284 Major goods/service lines Life Sciences Solutions $ 301,028 $ $ 301,028 $ 298,052 $ $ 298,052 Software 57,671 57,671 67,846 67,846 Immunodiagnostics 214,758 214,758 218,818 218,818 Reproductive Health 156,231 156,231 135,568 135,568 $ 358,699 $ 370,989 $ 729,688 $ 365,898 $ 354,386 $ 720,284 …
DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing
Fair value · 8,244 characters as filed
Fair Value Measurements Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities, accounts receivable and notes receivable. The Company believes it had no significant concentrations of credit risk as of July 5, 2026. The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the six months ended July 5, 2026. The Companys financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Companys currency risk, and acqu isition and divestiture related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerag …
FairValueDisclosuresTextBlock · excerpt; the full note is in the filing
Goodwill and intangibles · 2,472 characters as filed
Goodwill and Intangible Assets, Net The Company completes the annual testing of impairment for goodwill on the later of November 1 or the first day of its eleventh fiscal month of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill. The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill. The changes in the carrying amount of goodwill for the six months ended July 5, 2026 were as follows: Life Sciences Diagnostics Consolidated (In thousands) Balance at December 28, 2025 $ 4,744,962 $ 1,868,531 $ 6,613,493 Foreign currency translation (26,917) (10,588) (37,505) Acquisitions 31,814 31,814 Balance at July 5, 2026 $ 4,749,859 $ 1,857,943 $ 6,607,802 Identifiable intangible asset balances by category were as follows: July 5, 2026 December 28, 2025 (In thousands) Patents $ 27,591 $ 27,592 Less: Accumulated amortization (26,635) (26,524) Net patents 956 1,068 Trade names and trademarks 149,092 150,103 Less: Accumulated amortization (105,671) (102,234) Net trade names and …
GoodwillAndIntangibleAssetsDisclosureTextBlock · excerpt; the full note is in the filing
Restructuring · 2,365 characters as filed
Restructuring and Other Costs Restructuring and other costs in the first and second quarters of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. In the first and second quarters of fiscal year 20 26, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the Companys workforce. Restructuring and other costs in the first and second quarters of fiscal year 2025 primarily consisted of charges for workforce reductions and facility consolidations, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. Restructuring and other costs, which are included in the selling, general and administrative expenses in the consolidated statements of operations, by segment were as follows: Three Months Ended Six Months Ended July 5, 2026 June 29, 2025 July 5, 2026 June 29, 2025 (In thousands) Life Sciences $ 5,926 $ 1,917 $ 9,155 $ 4,445 Diagnostics 29,582 9,233 37,136 9,368 Corporate 53 (108) 629 $ 35,508 $ 11,203 $ 46,183 $ 14,442 The following table summarizes the changes in the Companys accrued restructuring balance for the six months ended July 5, 20 …
RestructuringAndRelatedActivitiesDisclosureTextBlock · excerpt; the full note is in the filing
Revenue recognition · 4,737 characters as filed
Revenue Disaggregation of revenue Disaggregated revenue by primary geographical markets and major goods and service lines are as follows: Reportable Segments Three Months Ended July 5, 2026 June 29, 2025 Life Sciences Diagnostics Total Life Sciences Diagnostics Total (In thousands) Primary geographical markets Americas $ 183,575 $ 142,008 $ 325,583 $ 197,071 $ 126,509 $ 323,580 Europe 89,478 139,563 229,041 84,298 119,334 203,632 Asia 85,646 89,418 175,064 84,529 108,543 193,072 $ 358,699 $ 370,989 $ 729,688 $ 365,898 $ 354,386 $ 720,284 Major goods/service lines Life Sciences Solutions $ 301,028 $ $ 301,028 $ 298,052 $ $ 298,052 Software 57,671 57,671 67,846 67,846 Immunodiagnostics 214,758 214,758 218,818 218,818 Reproductive Health 156,231 156,231 135,568 135,568 $ 358,699 $ 370,989 $ 729,688 $ 365,898 $ 354,386 $ 720,284 Reportable Segments Six Months Ended July 5, 2026 June 29, 2025 Life Sciences Diagnostics Total Life Sciences Diagnostics Total (In thousands) Primary geographical markets Americas $ 369,126 $ 272,449 $ 641,575 $ 381,350 $ 246,859 $ 628,209 Europe 181,173 270,914 452,087 160,320 225,104 385,424 Asia 170,245 176,899 347,144 164,623 206,790 371,413 $ 720,544 $ 720,262 $ 1,440,806 $ 706,293 $ 678,753 $ 1,385,046 Major goods/service lines Life Sciences Solutions $ 601,024 $ $ 601,024 $ 584,505 $ $ 584,505 Software 119,520 119,520 121,788 121,788 Immunodiagnostics 416,589 416,589 416,380 416,380 Reproductive Health 303,673 303,673 262,373 262,373 $ 720,544 $ 7 …
RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing
Segment reporting · 4,839 characters as filed
Segment Information The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Companys chief operating decision maker (CODM) is the Chief Executive Officer (CEO). The CEO evaluates the performance of the Companys operating segments based on revenue and operating income as adjusted for certain items. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1, Nature of Operations and Accounting Policies, to the audited consolidated financial statements in the 2025 Form 10-K. The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as Corporate below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Companys calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the bus …
SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing
Stockholders' equity · 4,250 characters as filed
Stockholders Equity Comprehensive Income: The components of accumulated other comprehensive loss consisted of the following: July 5, 2026 December 28, 2025 (In thousands) Foreign currency translation adjustments, net of income taxes $ (256,552) $ (221,062) Unrecognized prior service costs, net of income taxes (798) Unrealized net losses on marketable securities, net of income taxes (2) (275) Accumulated other comprehensive loss $ (256,554) $ (222,135) The unrealized foreign exchange losses (gains), net of income taxes, on intercompany debt for which repayment is not anticipated in the foreseeable future that was recorded in accumulated other comprehensive income (AOCI) were $2.4 million and $(157.5) million for the three months ended July 5, 2026 and June 29, 2025, respectively, and $42.3 million and $(228.6) million for the six months ended July 5, 2026 and June 29, 2025, respectively. The income tax effects associated with foreign currency translation adjustments recognized in AOCI reflected a tax expense of $0.5 million and $3.1 million for the three months ended July 5, 2026 and June 29, 2025, respectively. The income tax effects associated with foreign currency translation adjustments recognized in AOCI reflected a tax benefit of $12.4 million and $1.1 million for the six months ended July 5, 2026 and June 29, 2025, respectively. Stock Repurchases: On October 23, 2025 , the Companys Board of Directors (the Board) authorized the Company to repurchase shares of common stoc …
StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing
Subsequent events · 343 characters as filed
Subsequent EventsOn July 31, 2026, the Company entered into a definitive agreement to divest its Immunodiagnostics business in China, which represented approximately 6% of the Companys total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals. …
SubsequentEventsTextBlock · excerpt; the full note is in the filing
Source: SEC DERA Financial Statement and Notes data sets (txt.tsv), excerpts of the filer's own note text; the full note is in the linked filing. Excerpts are the first part of each note exactly as tagged in the filing; open the filing for the full text and the tables. Descriptive and educational, not advice.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.